CEO Update - 1 July 2024

UK General Election


I will watch the General Election this Thursday with great interest, like the rest of the country, and update you on the new ministers and members of Parliament next week. You can access the policy backgrounds of the main parties and view our webinar on what the campaign has taught us about what our sector should expect from the new parliament and government. It was interesting to see global business voices recognising an opportunity in medicines manufacturing if the new UK government gets its act together on planning.

Join us in Glasgow tomorrow

I'm in Scotland this week for our Glasgow regional event and look forward to learning more about the clinical trial capability, particularly in the West of Scotland and amongst our members. Ensuring we have a clinical trial system in the NIHR and a regulatory system around the MHRA that delivers on time and on target is a key issue many members continue to race with me. I'm keen to learn more about your experience, positive and negative, to gain a full picture of where the UK system stands in relation to international peers through 2024. It's a topic that I'm sure will be at the heart of our joint conference with the MHRA later in the year.

Women in Biotech 

Bristol welcomed Women in Biotech to town very warmly last Thursday, with the Bristol BioDesign Institute hosting the event at the university. An inspiring panel of female founders, entrepreneurs and experts spoke candidly about both the challenges and opportunities for female leadership in the Deep Biotech space and many connections were made.

Vision for life sciences

If you've heard one of my speeches at a BIA event this year, you're aware that we're in the process of updating our sector's vision for the next ten years. Back in 2015, we set out to establish the sector as the third global cluster by 2025. Now is an ideal time to review our progress and plan for the future. Your assistance is crucial. This week, we plan to survey a broad group of BIA members regarding our initial ideas, and I would greatly value your input. Keep an eye out for an email later this week.

Last chance to secure your attendance at our Summer Party - I do hope you can join us!

 

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

CEO Update - 8 July 2024

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Brandon Capital's vision for a transcontinental life science axis

Jonathan Tobin, Partner at Brandon Capital, discusses the firm's recent close of its sixth fund at A$270 million, bringing its total assets under management to over A$1.25 billion. He also explores how Brandon Capital is strategically connecting Australia, New Zealand, the UK, and the US.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

PIR International interview with Anja Harmeier, CEO, Rewind Therapeutics

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

More within